These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 12017000)
1. [Synthesis and antiosteoporosis activity of steroid-bisphosphonate compounds]. Zheng H; Wu Y; Chen J; Weng L Yao Xue Xue Bao; 1998 May; 33(5):339-43. PubMed ID: 12017000 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro. Xie Y; Ding H; Qian L; Yan X; Yang C; Xie Y Bioorg Med Chem Lett; 2005 Jul; 15(13):3267-70. PubMed ID: 15936189 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Morioka M; Kamizono A; Takikawa H; Mori A; Ueno H; Kadowaki S; Nakao Y; Kato K; Umezawa K Bioorg Med Chem; 2010 Feb; 18(3):1143-8. PubMed ID: 20071185 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and biological activity of hydroxyl-bisphosphonic analogs of bile acids. Bortolini O; Fantin G; Fogagnolo M; Rossetti S; Maiuolo L; Di Pompo G; Avnet S; Granchi D Eur J Med Chem; 2012 Jun; 52():221-9. PubMed ID: 22483634 [TBL] [Abstract][Full Text] [Related]
6. [Studies of drugs for osteoporosis (3): synthesis of quinolinone derivatives and their treatment of osteoporosis]. Xu MX; Duan WH; Zheng H Yao Xue Xue Bao; 1995; 30(10):792-5. PubMed ID: 8701736 [TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation. Sawicki M; Lecerclé D; Grillon G; Le Gall B; Sérandour AL; Poncy JL; Bailly T; Burgada R; Lecouvey M; Challeix V; Leydier A; Pellet-Rostaing S; Ansoborlo E; Taran F Eur J Med Chem; 2008 Dec; 43(12):2768-77. PubMed ID: 18313802 [TBL] [Abstract][Full Text] [Related]
8. [Bisphosphonate therapy for osteoporosis and bone strength]. Kishimoto H Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477 [TBL] [Abstract][Full Text] [Related]
9. A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues. Margiotta N; Capitelli F; Ostuni R; Natile G J Inorg Biochem; 2008 Dec; 102(12):2078-86. PubMed ID: 18760482 [TBL] [Abstract][Full Text] [Related]
10. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats. Aspenberg P; Wermelin K; Tengwall P; Fahlgren A Acta Orthop; 2008 Feb; 79(1):111-5. PubMed ID: 18283582 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate modulates morphological and mechanical properties in distraction osteogenesis through inhibition of bone resorption. Takahashi M; Yukata K; Matsui Y; Abbaspour A; Takata S; Yasui N Bone; 2006 Sep; 39(3):573-81. PubMed ID: 16713413 [TBL] [Abstract][Full Text] [Related]
12. [Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP)]. Masaki H; Miki T Clin Calcium; 2006 Nov; 16(11):1823-32. PubMed ID: 17079849 [TBL] [Abstract][Full Text] [Related]
13. Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates. El-Sayed NF; El-Hussieny M; Mansour ST; Fouad MA; Saad MA; Ewies EF Eur J Med Chem; 2024 Oct; 276():116679. PubMed ID: 39018923 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of isoprenoid bisphosphonates. Shull LW; Wiemer AJ; Hohl RJ; Wiemer DF Bioorg Med Chem; 2006 Jun; 14(12):4130-6. PubMed ID: 16517172 [TBL] [Abstract][Full Text] [Related]
15. [Experimental analysis of initial and appositional mineralization of biological hard tissues in bisphosphonate-affected animals]. Takano Y; Sakai H; Ohma N Kaibogaku Zasshi; 2000 Aug; 75(4):351-5. PubMed ID: 11025942 [No Abstract] [Full Text] [Related]
16. Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions. Arstad E; Hoff P; Skattebøl L; Skretting A; Breistøl K J Med Chem; 2003 Jul; 46(14):3021-32. PubMed ID: 12825941 [TBL] [Abstract][Full Text] [Related]
17. A combination of bisphosphonate and BMP additives in impacted bone allografts. Jeppsson C; Astrand J; Tägil M; Aspenberg P Acta Orthop Scand; 2003 Aug; 74(4):483-9. PubMed ID: 14521303 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128 [TBL] [Abstract][Full Text] [Related]
19. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877 [TBL] [Abstract][Full Text] [Related]
20. Prior bisphosphonate therapy of osteoporosis attenuates and blocks response to subsequent parathyroid hormone. Handler RP J Clin Rheumatol; 2008 Apr; 14(2):122-4. PubMed ID: 18391687 [No Abstract] [Full Text] [Related] [Next] [New Search]